I need an Anki card import-ready for [ALL]. Output rules — read carefully and follow exactly: 1. Output ONLY one single line of plain text. No introduction, no explanation, no code block, no triple backticks, nothing else. 2. The line has exactly TWO fields separated by a single TAB character. 3. Field 1 (Front): [TOPIC NAME] – Complete Pathology (NEET PG 2026) 4. Field 2 (Back): All content in a single continuous string using ONLY these HTML tags: <b> for bold, <i> for italic, <br> for line breaks. NO markdown, NO asterisks, NO hyphens as bullets — use • character instead. 5. Content must cover: definition → genetic/molecular basis → pathophysiology step by step → organ-specific pathology → clinical features → peripheral smear → lab findings → diagnosis → differentials → management (pathology-linked) → NEET PG exam pearls one-liners. 6. The entire Back field must be one unbroken string with NO newlines — only <br> tags for breaks. 7. Anki import: Tab separator, Field 1 = Front, Field 2 = Back, Allow HTML = ON.
[TOPIC NAME] – Complete Pathology (NEET PG 2026) Definition: [Add crisp definition of ALL here: malignant clonal proliferation of lymphoid precursors in bone marrow with spillover to blood and tissue infiltration.]
Genetic/Molecular Basis: • Common alterations: t(12;21) ETV6-RUNX1, hyperdiploidy, t(1;19) TCF3-PBX1, BCR-ABL1 t(9;22) (high risk), KMT2A(MLL) rearrangements (infant, poor risk), hypodiploidy, IKZF1 alterations • B-ALL markers: CD10, CD19, CD22, CD79a, TdT • T-ALL markers: CD2, CD3, CD5, CD7, TdT • Molecular events cause differentiation arrest, uncontrolled proliferation, apoptosis escape
Pathophysiology (Stepwise): • Driver mutation in lymphoid progenitor • Maturation arrest at lymphoblast stage • Marrow replacement by blasts • Suppression of erythropoiesis, granulopoiesis, thrombopoiesis • Peripheral cytopenias (anemia, neutropenia, thrombocytopenia) • Blood blast spillover • Extramedullary infiltration (liver, spleen, nodes, CNS, testes, mediastinum in T-ALL) • Cytokine/inflammatory effects contribute to fever, bone pain, constitutional symptoms
Organ-Specific Pathology: • Bone marrow: hypercellular, packed with lymphoblasts (>20%) • Blood: circulating blasts, cytopenias • Lymph nodes/spleen/liver: infiltration causing lymphadenopathy, hepatosplenomegaly • CNS: meningeal infiltration (headache, vomiting, cranial nerve signs) • Testes: sanctuary site, painless enlargement • Thymus/mediastinum (T-ALL): mass, SVC obstruction risk
Clinical Features: • Fatigue, pallor, fever • Recurrent infections • Bleeding manifestations (petechiae, epistaxis, gum bleed) • Bone/joint pain, limp in children • Lymphadenopathy, hepatosplenomegaly • CNS symptoms in advanced/relapse disease • Testicular swelling (boys) • Mediastinal compression symptoms in T-ALL (cough, dyspnea)
Peripheral Smear: • Lymphoblasts: high N:C ratio, scant agranular cytoplasm, fine chromatin, inconspicuous nucleoli (variable) • Anemia (usually normocytic normochromic) • Thrombocytopenia • Neutropenia • Auer rods absent (helps against AML)
Lab Findings: • CBC: Hb low, platelets low, WBC variable (low/normal/high) • Peripheral blasts may be present/absent early • Bone marrow aspirate/biopsy: blasts ≥20% (WHO criterion for acute leukemia) • Cytochemistry: MPO/Sudan Black negative in ALL blasts • Flow cytometry confirms lineage (B vs T) • LDH and uric acid elevated (high turnover) • Coagulation usually near normal unless sepsis/DIC overlap • CSF exam for CNS involvement during staging
Diagnosis: • Suspect from symptoms + CBC/smear • Confirm by marrow morphology + flow cytometry immunophenotype • Risk stratify using cytogenetics/molecular profile + MRD assessment • Baseline staging: CNS status, testicular exam, tumor burden, organ function before therapy
Differentials: • AML (MPO+, Auer rods may be present) • Leukemoid reaction • Infectious mononucleosis • Aplastic anemia (pancytopenia without blasts) • ITP (isolated thrombocytopenia) • Juvenile idiopathic arthritis/rheumatic disease (bone pain mimic) • Lymphoblastic lymphoma (mass dominant, minimal marrow disease)
Management (Pathology-Linked): • Supportive: transfusions, infection control, TLS prophylaxis (hydration, allopurinol/rasburicase) • Multi-phase chemotherapy: induction (remission), consolidation/intensification, maintenance • CNS-directed therapy: intrathecal methotrexate ± cranial irradiation in selected high-risk cases • Targeted therapy by molecular lesion: TKIs for Ph+ ALL (e.g., imatinib/dasatinib) • Immunotherapy in relapsed/refractory disease: blinatumomab (CD19), inotuzumab (CD22), CAR-T (CD19) • HSCT for high-risk/relapsed groups based on MRD/genetics • MRD-guided treatment adaptation is key prognostic tool
NEET PG Exam Pearls (One-liners): • Most common childhood acute leukemia = ALL • Marrow blasts ≥20% define acute leukemia (WHO) • TdT positivity supports precursor lymphoid blasts • MPO negativity favors ALL over AML • t(12;21) and hyperdiploidy carry favorable prognosis • Ph+ ALL (t(9;22)) has poor risk but improved outcomes with TKI • T-ALL often presents with mediastinal mass • CNS and testes are classic sanctuary sites • Elevated LDH/uric acid indicate high cell turnover and TLS risk • MRD is the strongest post-induction prognostic marker
Genetic/Molecular Basis: • Common alterations: t(12;21) ETV6-RUNX1, hyperdiploidy, t(1;19) TCF3-PBX1, BCR-ABL1 t(9;22) (high risk), KMT2A(MLL) rearrangements (infant, poor risk), hypodiploidy, IKZF1 alterations • B-ALL markers: CD10, CD19, CD22, CD79a, TdT • T-ALL markers: CD2, CD3, CD5, CD7, TdT • Molecular events cause differentiation arrest, uncontrolled proliferation, apoptosis escape
Pathophysiology (Stepwise): • Driver mutation in lymphoid progenitor • Maturation arrest at lymphoblast stage • Marrow replacement by blasts • Suppression of erythropoiesis, granulopoiesis, thrombopoiesis • Peripheral cytopenias (anemia, neutropenia, thrombocytopenia) • Blood blast spillover • Extramedullary infiltration (liver, spleen, nodes, CNS, testes, mediastinum in T-ALL) • Cytokine/inflammatory effects contribute to fever, bone pain, constitutional symptoms
Organ-Specific Pathology: • Bone marrow: hypercellular, packed with lymphoblasts (>20%) • Blood: circulating blasts, cytopenias • Lymph nodes/spleen/liver: infiltration causing lymphadenopathy, hepatosplenomegaly • CNS: meningeal infiltration (headache, vomiting, cranial nerve signs) • Testes: sanctuary site, painless enlargement • Thymus/mediastinum (T-ALL): mass, SVC obstruction risk
Clinical Features: • Fatigue, pallor, fever • Recurrent infections • Bleeding manifestations (petechiae, epistaxis, gum bleed) • Bone/joint pain, limp in children • Lymphadenopathy, hepatosplenomegaly • CNS symptoms in advanced/relapse disease • Testicular swelling (boys) • Mediastinal compression symptoms in T-ALL (cough, dyspnea)
Peripheral Smear: • Lymphoblasts: high N:C ratio, scant agranular cytoplasm, fine chromatin, inconspicuous nucleoli (variable) • Anemia (usually normocytic normochromic) • Thrombocytopenia • Neutropenia • Auer rods absent (helps against AML)
Lab Findings: • CBC: Hb low, platelets low, WBC variable (low/normal/high) • Peripheral blasts may be present/absent early • Bone marrow aspirate/biopsy: blasts ≥20% (WHO criterion for acute leukemia) • Cytochemistry: MPO/Sudan Black negative in ALL blasts • Flow cytometry confirms lineage (B vs T) • LDH and uric acid elevated (high turnover) • Coagulation usually near normal unless sepsis/DIC overlap • CSF exam for CNS involvement during staging
Diagnosis: • Suspect from symptoms + CBC/smear • Confirm by marrow morphology + flow cytometry immunophenotype • Risk stratify using cytogenetics/molecular profile + MRD assessment • Baseline staging: CNS status, testicular exam, tumor burden, organ function before therapy
Differentials: • AML (MPO+, Auer rods may be present) • Leukemoid reaction • Infectious mononucleosis • Aplastic anemia (pancytopenia without blasts) • ITP (isolated thrombocytopenia) • Juvenile idiopathic arthritis/rheumatic disease (bone pain mimic) • Lymphoblastic lymphoma (mass dominant, minimal marrow disease)
Management (Pathology-Linked): • Supportive: transfusions, infection control, TLS prophylaxis (hydration, allopurinol/rasburicase) • Multi-phase chemotherapy: induction (remission), consolidation/intensification, maintenance • CNS-directed therapy: intrathecal methotrexate ± cranial irradiation in selected high-risk cases • Targeted therapy by molecular lesion: TKIs for Ph+ ALL (e.g., imatinib/dasatinib) • Immunotherapy in relapsed/refractory disease: blinatumomab (CD19), inotuzumab (CD22), CAR-T (CD19) • HSCT for high-risk/relapsed groups based on MRD/genetics • MRD-guided treatment adaptation is key prognostic tool
NEET PG Exam Pearls (One-liners): • Most common childhood acute leukemia = ALL • Marrow blasts ≥20% define acute leukemia (WHO) • TdT positivity supports precursor lymphoid blasts • MPO negativity favors ALL over AML • t(12;21) and hyperdiploidy carry favorable prognosis • Ph+ ALL (t(9;22)) has poor risk but improved outcomes with TKI • T-ALL often presents with mediastinal mass • CNS and testes are classic sanctuary sites • Elevated LDH/uric acid indicate high cell turnover and TLS risk • MRD is the strongest post-induction prognostic marker
This is a shared conversation. Sign in to Orris to start your own chat.